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review articles for cost-effectiveness studies of ulcerative colitis (UC) and to evaluate 
analytical approaches that can be applied to Japanese environment. Methods: The 
literature search was conducted in MEDLINE and JDream III. Inclusion criteria are 
studies of 1) treatment for UC, 2) cost-effectiveness analysis (CEA), 3) published in 
the past 10 years. Studies were assessed for the followings: country, model struc-
ture and simulation method, time horizon, perspective, source of key parameters, 
results, and key drivers determined from sensitivity analysis. Results: Nine 
studies were reviewed in details. Markov (6 articles) and decision tree (2 articles) 
models were adopted, and time horizon varied from 12 weeks of clinical trial peri-
ods to lifetime. Studies additionally considering surgery and treatment costs of 
colorectal cancer referred to other studies or official medical fees. Utility scores 
were referred to other studies (9 articles). Disutility of surgery was estimated based 
on assumptions. Parameters which became key drivers for these analyses varied 
among studies. ConClusions: Data collection methods adopted in prior studies 
were applicable to CEA for UC in Japan. Cost data can be obtained not only from 
questionnaire survey to doctors but commercial database. Because evidence on 
utility scores of Japanese population is still limited, further studies will be needed, 
especially on patients in different phases of UC treatment.
PGI24
EvaluatInG thE Cost-EffECtIvEnEss of ProlonGEd-rElEasE taCrolImus 
rElatIvE to ImmEdIatE-rElEasE taCrolImus In lIvEr transPlant 
PatIEnts BasEd on data from routInE ClInICal PraCtICE
Muduma G1, Odeyemi IA1, Pollock RF2
1Astellas Pharma Europe Ltd, Chertsey, UK, 2Ossian Health Economics and Communications 
GmbH, Basel, Switzerland
objeCtives: As of 2014, there were approximately 8,300 patients with a functioning 
liver transplant in the UK Transplant Registry, with 880 liver transplants performed 
in 2013–14 alone. As the number of surviving liver transplant recipients continues to 
increase, healthcare expenditure in these patients should be periodically reviewed 
to maximize value for money. With tacrolimus representing the current cornerstone 
of post-transplant immunosuppressive therapy, the present study objective was to 
evaluate the cost-effectiveness of prolonged-release (PR) tacrolimus versus imme-
diate-release (IR) tacrolimus. Methods: A model was developed in Microsoft Excel 
to evaluate the cost and effectiveness of immunosuppressive regimens in liver 
transplant recipients. The model captured costs associated with immunosuppres-
sive medications, retransplantation and acute rejection. Three-year patient and graft 
survival data were taken from a recent retrospective European registry analysis and 
initial dose data were taken from the prescribing information. Costs were taken from 
the British National Formulary and the National Health Service National Tariff and 
expressed in 2014 pounds sterling. Results: Over a 3 year time horizon, the number 
needed to treat (NNT) with PR tacrolimus relative to IR tacrolimus was ~13 to avoid 
one graft loss and 17 to avoid one death. The model was sensitive to dosing assump-
tions, with incremental cost estimates varying between a saving of GBP 2,236 per 
treated patient, assuming the same dosing of PR and IR (per kilogram bodyweight) 
and an increase of GBP 781 using RCT dose data. ConClusions: Data from a recent 
analysis of routine clinical practice data in liver transplant recipients on PR and IR 
tacrolimus showed significant differences in long-term graft survival in favor of PR 
tacrolimus. Modeling these data in a UK population showed that, over a three-year 
time horizon one graft would be saved for approximately every 13 patients treated 
with PR tacrolimus with minimal impact on costs.
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objeCtives: Hepatic encephalopathy (HE) is associated with high morbidity and 
mortality. Rifaximin-α 550mg reduces the recurrence of episodes of overt HE. We 
determined the cost effectiveness of rifaximin-α 550mg versus standard care (lactu-
lose) in patients with cirrhosis in the UK. Methods: This economic evaluation used 
a Markov state transition model. The outcome metric was the ICER, derived from 
estimates of the cost/QALYs. The payer perspective was that of UK National Health 
Service. Outcome data were from two rifaximin-α 550mg trials. Population outcome 
data were from a complementary study of patients with liver cirrhosis treated within 
the NHS. UK Costs data (2012) were derived from published sources. Health-related 
utility was estimated indirectly from disease-specific quality of life RCT data. The 
time horizon was five years. Costs and benefits were discounted at 3.5%. Extensive 
sensitivity analyses were carried out. Real world data describing the use of rifaximin-α 
550mg in the UK NHS were also applied into the model for length of stay in hospital 
and the number of admissions. Results: The average cost for the included elements 
of care was £22,971 for rifaximin-α 550mg and £23,545 for lactulose, a difference of 
-£573. The corresponding values for benefit were 2.36 QALYs/person and 1.83 QALYs/
person, respectively, a difference of 0.53 QALYs. This translated into a dominant base-
case ICER. Key parameters that impacted the ICER included length of stay in hospital 
and the number of admissions to hospital. Evaluation to 10 years and lifetime resulted 
in ICERs of £4,470/QALY and £7,215/QALY, respectively. ConClusions: Rifaximin-α 
550mg in patients with recurrent HE in the context of liver cirrhosis represented good 
value for money compared to standard care, by reducing episodes of overt HE, the 
likelihood of hospital admission and hospital length of stay.
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objeCtives: The purpose of this study was to analyze the cost-effectiveness of the 
association of everolimus (EVR) with reduced tacrolimus doses (rTAC) in liver trans-
plantation patients with renal dysfunction. Methods: A cost-effectiveness analysis 
zole, omeprazole or pantoprazole (the QALY gains were 0.0002, 0.0003 and 0.0003, 
respectively). There were also marginal cost savings achieved by esomeprazole 
(1.23 EUR versus lansoprazole, 2.27 EUR versus omeprazole and 1.51 EUR versus 
pantoprazole), therefore esomeprazole was projected to have a dominant position 
versus other PPIs in the cost-effectiveness analysis. ConClusions: Esomeprazole 
provides greater effectiveness at a lower cost compared with other PPIs currently 
reimbursed in Poland in the treatment of GERD.
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objeCtives: Hepatic encephalopathy (HE) is associated with high morbid-
ity and mortality. Rifaximin-α 550mg reduces the recurrence of episodes of 
overt HE, and hospital utilisation. We characterised the cost effectiveness of 
rifaximin-α 550mg versus standard care (lactulose) in patients with liver cirrhosis 
in Sweden. Methods: This economic evaluation used a Markov state transition 
model. The outcome metric was the ICER, derived from estimates of the cost/QALYs. 
The payer perspective was that of the Swedish healthcare system. Outcome data 
were from two rifaximin-α 550mg trials. Population outcome data were from a 
complementary study of patients with liver cirrhosis treated in Sweden. Swedish 
Costs data (2012) were derived from published sources. Health-related utility was 
estimated indirectly from disease-specific quality of life RCT data. The time horizon 
was five years. Costs and benefits were discounted at 3.5%. Extensive sensitivity 
analyses were carried out. Real world data were also applied into the model for 
length of stay in hospital and the number of admissions. Results: The average cost 
of the included elements of care was SEK302,520 (€ 32,667) for rifaximin-α 550mg 
and SEK393,777 (€ 42,522) for lactulose, a difference of -SEK91,257 (-€ 9,854). The 
corresponding values for benefit were 2.38 QALYs/person and 1.83 QALYs/person, 
respectively, a difference of 0.55 QALYs over the five year period. This translated into 
a dominant base-case ICER at five years, meaning that rifaximin-α 550mg was both 
less costly and more beneficial. Key parameters that impacted the ICER included 
length of stay in hospital and the number of admissions to hospital. Evaluation to 
10 years also resulted in a dominant ICER, although the lifetime ICER was SEK5,918 
(€ 639) per QALY. ConClusions: In Sweden, treatment with rifaximin-α 550mg 
in patients with recurrent HE in the context of liver cirrhosis was cost effective 
compared to standard care, by reducing episodes of overt HE.
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objeCtives: This study aimed to estimate the cost-effectiveness ratio of eltrom-
bopag in the treatment of thrombocytopenia during antiviral therapy (AVT) in 
HCV-patients with advanced liver disease (ALD) in Italy. Methods: The economic 
assessment was conducted according to a Markov model, which enabled the 
evolution of hypothetical cohorts of patients undergoing different diagnosis and 
treatment protocols and the respective costs and benefits to be quantified. Three 
alternative scenarios were set up: 1) eltrombopag treatment in both enabling phase 
and during AVT; 2) no eltrombopag and no AVT; 3) no eltrombopag treatment and 
administration of a reduced dose of peg-IFN (according to platelet count), and no 
peg-IFN treatment for patients with the lowest platelet count. Parameter uncertainty 
and robustness of the results were assessed through a one-way sensitivity analysis 
and a multivariate probabilistic sensitivity analysis. Results: The results demon-
strate that scenario 1 is associated with a cost per QALY of € 30,020.94 in comparison 
with scenario 2. The ICER reaches a value of 2,752.44 € /QALY when scenario 1 is 
compared with scenario 3. The ICERs therefore are considered sustainable consid-
ering the threshold value generally taken into account by NICE (20,000–40,000 € /
QALY). ConClusions: The use of eltrombopag in thrombocytopenic HCV-patients 
can increase sustained virological response, leading to a reduction in disease pro-
gression and thus a drop in the number of patients with ALD. Preventing the onset 
of complications and acting early to reduce the incidence of complex conditions 
that absorb more resources thus seems a rational choice that is consistent with 
the patient’s preferences and the needs of the healthcare system. This economic 
assessment suggests that eltrombopag administration is indicated.
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objeCtives: Ministry of Health, Labour and Welfare of Japan aims for the intro-
duction of Health Technology Assessment in FY2016. Compared to foreign coun-
tries, a lack of resources for conducting the analysis has been pointed out in Japan. 
However, pharmaceutical and medical device industries are urged to seek practical 
approaches utilizing best available resources. The objective of this study was to 
